ESR1 and cancer: Inhibitionof PI3K activity, on the one hand, can suppress the estrogen-inducedG1 to S phase transition in the cell cycle, mimicking the effect ofCDK inhibitors.68,69 On the other hand, it can enhanceestrogen’s apoptosis-inducing effect in ERα-positivebreast cancer cells.